Avadel Pharmaceuticals plc (AVDL)
- Previous Close
17.82 - Open
17.75 - Bid 17.80 x 500
- Ask 17.91 x 100
- Day's Range
17.71 - 18.22 - 52 Week Range
9.50 - 18.85 - Volume
452,255 - Avg. Volume
1,204,393 - Market Cap (intraday)
1.613B - Beta (5Y Monthly) 1.63
- PE Ratio (TTM)
-- - EPS (TTM)
-2.00 - Earnings Date Mar 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.90
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
www.avadel.com154
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AVDL
Performance Overview: AVDL
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVDL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVDL
Valuation Measures
Market Cap
1.61B
Enterprise Value
1.51B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
51.06
Price/Book (mrq)
18.40
Enterprise Value/Revenue
54.03
Enterprise Value/EBITDA
-10.13
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-57.92%
Return on Equity (ttm)
-481.35%
Revenue (ttm)
27.96M
Net Income Avi to Common (ttm)
-160.28M
Diluted EPS (ttm)
-2.00
Balance Sheet and Cash Flow
Total Cash (mrq)
105.11M
Total Debt/Equity (mrq)
40.33%
Levered Free Cash Flow (ttm)
-77.95M